{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:06:18Z","timestamp":1793196378545,"version":"4.5.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.neuropharm.2017.10.007","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T00:02:08Z","timestamp":1507852928000},"page":"65-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"PA","title":["MDPV and \u03b1-PVP use in humans: The twisted sisters"],"prefix":"10.1016","volume":"134","author":[{"given":"Laurent","family":"Karila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Lafaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Scocard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Cottencin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine","family":"Benyamina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.neuropharm.2017.10.007_bib1","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s00213-015-3944-8","article-title":"In\u00a0vivo potency and efficacy of the novel cathinone alpha-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats","volume":"232","author":"Aarde","year":"2015","journal-title":"Psychopharmacol. Berl."},{"issue":"5","key":"10.1016\/j.neuropharm.2017.10.007_bib2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/02791072.2015.1094591","article-title":"The new designer drug wave: a clinical, toxicological, and legal analysis","volume":"47","author":"Abbott","year":"2015","journal-title":"J.\u00a0Psychoact. Drugs"},{"issue":"5","key":"10.1016\/j.neuropharm.2017.10.007_bib3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/jat\/bkt025","article-title":"Analysis of MDPV in blood\u2013determination and interpretation","volume":"37","author":"Adamowicz","year":"2013","journal-title":"J.\u00a0Anal. Toxicol."},{"issue":"4","key":"10.1016\/j.neuropharm.2017.10.007_bib4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.emc.2015.07.006","article-title":"New drugs of abuse and withdrawal syndromes","volume":"33","author":"Andrabi","year":"2015","journal-title":"Emerg. Med. Clin. North Am."},{"issue":"5","key":"10.1016\/j.neuropharm.2017.10.007_bib5","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/02791072.2016.1229875","article-title":"Patterns of use, acute subjective experiences, and motivations for using synthetic cathinones (\u201cBath salts\u201d) in recreational users","volume":"48","author":"Ashrafioun","year":"2016","journal-title":"J.\u00a0Psychoact. Drugs"},{"issue":"5","key":"10.1016\/j.neuropharm.2017.10.007_bib6","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jemermed.2013.11.104","article-title":"Synthetic cathinones (\u201cbath salts\u201d)","volume":"46","author":"Banks","year":"2014","journal-title":"J.\u00a0Emerg. Med."},{"issue":"4","key":"10.1016\/j.neuropharm.2017.10.007_bib7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/npp.2012.204","article-title":"Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products","volume":"38","author":"Baumann","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2017.10.007_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2012.11.020","article-title":"Psychoactive \u201cbath salts\u201d: not so soothing","volume":"698","author":"Baumann","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/7854_2016_53","article-title":"Neuropharmacology of 3,4-methylenedioxypyrovalerone (MDPV), its metabolites, and related analogs","volume":"32","author":"Baumann","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib10","series-title":"Pyrrolidino Ketones","author":"Boehringer Ingelheim","year":"1967"},{"issue":"8","key":"10.1016\/j.neuropharm.2017.10.007_bib11","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/dta.2151","article-title":"Alpha-PVP as an active component of herbal highs in Poland between 2013 and 2015","volume":"9","author":"Byrska","year":"2017","journal-title":"Drug Test. Anal."},{"issue":"3","key":"10.1016\/j.neuropharm.2017.10.007_bib12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00213-013-2967-2","article-title":"Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of \u201cbath salts,\u201d produce opposite effects at the human dopamine transporter","volume":"227","author":"Cameron","year":"2013","journal-title":"Psychopharmacol. Berl."},{"issue":"5","key":"10.1016\/j.neuropharm.2017.10.007_bib13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00213-017-4526-8","article-title":"Behavioral evidence for the abuse potential of the novel synthetic cathinone alpha-pyrrolidinopentiothiophenone (PVT) in rodents","volume":"234","author":"Cheong","year":"2017","journal-title":"Psychopharmacol. Berl."},{"issue":"1","key":"10.1016\/j.neuropharm.2017.10.007_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.toxlet.2011.10.002","article-title":"3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online","volume":"208","author":"Coppola","year":"2012","journal-title":"Toxicol. Lett."},{"issue":"25","key":"10.1016\/j.neuropharm.2017.10.007_bib15","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.2174\/13816128113199990622","article-title":"New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature","volume":"20","author":"Cottencin","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib16","first-page":"3460849","article-title":"Flakka-induced Prolonged Psychosis","volume":"2016","author":"Crespi","year":"2016","journal-title":"Case Rep Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.10.007_bib17","series-title":"Schedules of Controlled Substances: Placement of 10 Synthetic Cathinones into Schedule I in","author":"DEA","year":"2017"},{"issue":"2","key":"10.1016\/j.neuropharm.2017.10.007_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/03602532.2016.1188937","article-title":"Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases","volume":"48","author":"Ellefsen","year":"2016","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib19","series-title":"EMCDDA\u2013europol Joint Report on a New Psychoactive Substance: MDPV (3,4-methylenedioxypyrovalerone), Joint Reports","author":"EMCDDA, European Monitoring Centre for Drugs and Drug Addiction","year":"2014"},{"key":"10.1016\/j.neuropharm.2017.10.007_bib20","series-title":"EMCDDA\u2013europol Joint Report on a New Psychoactive Substance: 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (\u03b1-PVP), Joint Reports","author":"EMCDDA, European Monitoring Centre for Drugs and Drug Addiction","year":"2015"},{"key":"10.1016\/j.neuropharm.2017.10.007_bib21","series-title":"Rapport europ\u00e9en sur les drogues 2016","author":"EMCDDA, Observatoire europ\u00e9en des drogues et des toxicomanies","year":"2016"},{"key":"10.1016\/j.neuropharm.2017.10.007_bib22","series-title":"Europol (July 2016). Report on the Risk Assessment of 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (\u03b1-pyrrolidinovalerophenone, \u03b1-PVP)","author":"EMCDDA, European Monitoring Centre for Drugs and Drug Addiction","year":"2016"},{"key":"10.1016\/j.neuropharm.2017.10.007_bib23","series-title":"European Drug Report 2017: Trends and Developments","author":"EMCDDA, European Monitoring Centre for Drugs and Drug Addiction","year":"2017"},{"key":"10.1016\/j.neuropharm.2017.10.007_bib24","series-title":"Any Reports with Alpha-PVP. [Online] Erowid Experience Vault","author":"Erowid","year":"2017"},{"issue":"2","key":"10.1016\/j.neuropharm.2017.10.007_bib25","first-page":"82","article-title":"Designer drugs: a synthetic catastrophe","volume":"1","author":"Fratantonio","year":"2015","journal-title":"J.\u00a0Reward Defic. Syndr."},{"issue":"2","key":"10.1016\/j.neuropharm.2017.10.007_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s13181-014-0446-8","article-title":"Acute methylenedioxypyrovalerone toxicity","volume":"11","author":"Froberg","year":"2015","journal-title":"J.\u00a0Med. Toxicol."},{"issue":"7","key":"10.1016\/j.neuropharm.2017.10.007_bib27","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/FBP.0000000000000315","article-title":"Reinforcing effects of abused 'bath\u00a0salts' constituents 3,4-methylenedioxypyrovalerone and alpha-pyrrolidinopentiophenone and their enantiomers","volume":"28","author":"Gannon","year":"2017","journal-title":"Behav. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2017.10.007_bib28","first-page":"363","article-title":"\u201cBath Salts\u201d intoxication with multiorgan failure and left-sided ischemic colitis: a case report","volume":"19","author":"Gavriilidis","year":"2015","journal-title":"Hippokratia"},{"issue":"1","key":"10.1016\/j.neuropharm.2017.10.007_bib29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.lfs.2013.07.023","article-title":"Bath salts and synthetic cathinones: an emerging designer drug phenomenon","volume":"97","author":"German","year":"2014","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2807\/1560-7917.ES.2015.20.40.30036","article-title":"Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland, 2015","volume":"20","author":"Giese","year":"2015","journal-title":"Euro Surveill."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib31","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/B978-0-12-420118-7.00015-9","article-title":"Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention","volume":"69","author":"Glennon","year":"2014","journal-title":"Adv. Pharmacol."},{"issue":"Pt 1","key":"10.1016\/j.neuropharm.2017.10.007_bib32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.brainresbull.2016.04.011","article-title":"Neurobiology of 3,4-methylenedioxypyrovalerone (MDPV) and alpha-pyrrolidinovalerophenone (alpha-PVP)","volume":"126","author":"Glennon","year":"2016","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2015.12.020","article-title":"GC-MS analysis of the designer drug alpha-pyrrolidinovalerophenone and its metabolites in urine and blood in an acute poisoning case","volume":"259","author":"Grapp","year":"2016","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.neuropharm.2016.04.014","article-title":"Synthetic cathinone MDPV downregulates glutamate transporter subtype I (GLT-1) and produces rewarding and locomotor-activating effects that are reduced by a GLT-1 activator","volume":"108","author":"Gregg","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.10.007_bib35","series-title":"Arree\u02c6t\u00e9 du 27 juillet 2012 modifiant les arre\u02c6t\u00e9s du 22 f\u00e9vrier 1990 fixant la liste des substances class\u00e9es comme stup\u00e9fiants et la liste des substances psychotropes","author":"JO","year":"2012"},{"issue":"1","key":"10.1016\/j.neuropharm.2017.10.007_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2131\/jts.39.1","article-title":"New recreational drug 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP) activates central nervous system via dopaminergic neuron","volume":"39","author":"Kaizaki","year":"2014","journal-title":"J.\u00a0Toxicol. Sci."},{"issue":"9","key":"10.1016\/j.neuropharm.2017.10.007_bib37","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/dta.210","article-title":"GHB and synthetic cathinones: clinical effects and potential consequences","volume":"3","author":"Karila","year":"2011","journal-title":"Drug Test. Anal."},{"issue":"33","key":"10.1016\/j.neuropharm.2017.10.007_bib38","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.2174\/092986712803988839","article-title":"Diagnosis and consequences of cocaine addiction","volume":"19","author":"Karila","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"4 Pt 1","key":"10.1016\/j.neuropharm.2017.10.007_bib39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.lpm.2014.09.020","article-title":"Novel psychoactive substances: a review","volume":"44","author":"Karila","year":"2015","journal-title":"Presse Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2017.10.007_bib40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/1570159X13666141210224137","article-title":"Synthetic cathinones: a new public health problem","volume":"13","author":"Karila","year":"2015","journal-title":"Curr. Neuropharmacol."},{"issue":"42","key":"10.1016\/j.neuropharm.2017.10.007_bib41","doi-asserted-by":"crossref","first-page":"6420","DOI":"10.2174\/1381612822666160919093450","article-title":"The synthetic cannabinoids phenomenon","volume":"22","author":"Karila","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"8","key":"10.1016\/j.neuropharm.2017.10.007_bib42","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/jat\/bku073","article-title":"Suspected impaired driving case involving \u03b1-pyrrolidinovalerophenone, methylone and ethylone","volume":"38","author":"Knoy","year":"2014","journal-title":"J.\u00a0Anal. Toxicol."},{"issue":"12","key":"10.1016\/j.neuropharm.2017.10.007_bib43","first-page":"375","article-title":"Illicit bath salts: not for bathing","volume":"52","author":"Kyle","year":"2011","journal-title":"J.\u00a0Miss State Med. Assoc."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib44","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.forsciint.2016.02.017","article-title":"A\u00a0fatal intoxication related to MDPV and pentedrone combined with antipsychotic and antidepressant substances in Cyprus","volume":"265","author":"Liveri","year":"2016","journal-title":"Forensic Sci. Int."},{"issue":"3","key":"10.1016\/j.neuropharm.2017.10.007_bib45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jat\/bks136","article-title":"Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results","volume":"37","author":"Marinetti","year":"2013","journal-title":"J.\u00a0Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib46","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.neuropharm.2014.02.016","article-title":"Pharmacology of novel synthetic stimulants structurally related to the \u201cbath salts\u201d constituent 3,4-methylenedioxypyrovalerone (MDPV)","volume":"87","author":"Marusich","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.10.007_bib47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.neuro.2016.05.015","article-title":"Pharmacological effects of methamphetamine and alpha-PVP vapor and injection","volume":"55","author":"Marusich","year":"2016","journal-title":"Neurotoxicology"},{"issue":"4","key":"10.1016\/j.neuropharm.2017.10.007_bib48","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/jm050797a","article-title":"1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors","volume":"49","author":"Meltzer","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib49","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.annemergmed.2011.11.033","article-title":"Serotonin syndrome associated with MDPV use: a case report","volume":"60","author":"Mugele","year":"2012","journal-title":"Ann. Emerg. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2017.10.007_bib50","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13181-011-0196-9","article-title":"Death following recreational use of designer drug \u201cbath salts\u201d containing 3,4-Methylenedioxypyrovalerone (MDPV)","volume":"8","author":"Murray","year":"2012","journal-title":"J.\u00a0Med. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib51","doi-asserted-by":"crossref","unstructured":"Murray, B., Murphy, C. and Beuhler, M., Death following recreational use of designer drug \u2018\u2018bath salts\u2019\u2019 containing 3,4-methylenedioxypyrovalerone (MDPV). J. Med. Toxicol. 8: p. 69\u201375.","DOI":"10.1007\/s13181-011-0196-9"},{"issue":"1","key":"10.1016\/j.neuropharm.2017.10.007_bib52","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijcard.2013.12.262","article-title":"Sudden death after sustained restraint following self-administration of the designer drug alpha-pyrrolidinovalerophenone","volume":"172","author":"Nagai","year":"2014","journal-title":"Int. J. Cardiol."},{"issue":"11","key":"10.1016\/j.neuropharm.2017.10.007_bib53","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1038\/npp.2016.88","article-title":"Locomotor stimulant and rewarding effects of inhaling methamphetamine, MDPV, and mephedrone via electronic cigarette-type technology","volume":"41","author":"Nguyen","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.neuropharm.2017.10.007_bib54","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.genhosppsych.2012.06.005","article-title":"Excited delirium following use of synthetic cathinones (bath salts)","volume":"34","author":"Penders","year":"2012","journal-title":"Gen. Hosp. Psychiatry"},{"issue":"2","key":"10.1016\/j.neuropharm.2017.10.007_bib55","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/1556-4029.13326","article-title":"Fatal intoxication with alpha-PVP, a synthetic cathinone derivative","volume":"62","author":"Potocka-Banas","year":"2017","journal-title":"J.\u00a0Forensic Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2017.10.007_bib56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13181-011-0193-z","article-title":"The toxicology of bath salts: a review of synthetic cathinones","volume":"8","author":"Prosser","year":"2012","journal-title":"J.\u00a0Med. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib57","series-title":"Psychoactive Substances Act 2016 in","author":"PSA","year":"2016"},{"issue":"3","key":"10.1016\/j.neuropharm.2017.10.007_bib58","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.euroneuro.2014.12.012","article-title":"Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones","volume":"25","author":"Rickli","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib59","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11419-016-0309-x","article-title":"New psychoactive substance alpha-PVP in a traffic accident case","volume":"34","author":"Rojek","year":"2016","journal-title":"Forensic Toxicol."},{"issue":"6","key":"10.1016\/j.neuropharm.2017.10.007_bib60","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/15563650.2017.1301463","article-title":"Synthetic cathinones in Southern Germany - characteristics of users, substance-patterns, co-ingestions, and complications","volume":"55","author":"Romanek","year":"2017","journal-title":"Clin. Toxicol. (Phila)"},{"issue":"8","key":"10.1016\/j.neuropharm.2017.10.007_bib61","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00216-015-9247-4","article-title":"Determination of cathinones and other stimulant, psychedelic, and dissociative designer drugs in real hair samples","volume":"408","author":"Salomone","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"issue":"24","key":"10.1016\/j.neuropharm.2017.10.007_bib62","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1111\/bph.13640","article-title":"Pharmacological mechanisms underlying the cardiovascular effects of the \u201cbath salt\u201d constituent 3,4-methylenedioxypyrovalerone (MDPV)","volume":"173","author":"Schindler","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2017.10.007_bib63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.lpm.2016.11.014","article-title":"Synthetic cannabinoids: a new addiction matrix","volume":"46","author":"Scocard","year":"2017","journal-title":"Presse Med."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib64","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.forsciint.2015.01.003","article-title":"Fatal poisoning in drug addicts in the Nordic countries in 2012","volume":"248","author":"Simonsen","year":"2015","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib65","doi-asserted-by":"crossref","first-page":"288","DOI":"10.12659\/AJCR.889381","article-title":"\u201cBath salts\u201d induced severe reversible cardiomyopathy","volume":"14","author":"Sivagnanam","year":"2013","journal-title":"Am. J. Case Rep."},{"issue":"5","key":"10.1016\/j.neuropharm.2017.10.007_bib66","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/adb.12399","article-title":"Cocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys","volume":"22","author":"Smith","year":"2017","journal-title":"Addict. Biol."},{"issue":"1","key":"10.1016\/j.neuropharm.2017.10.007_bib67","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00213-016-4444-1","article-title":"Cocaine-like discriminative stimulus effects of amphetamine, cathinone, methamphetamine, and their 3,4-methylenedioxy analogs in male rhesus monkeys","volume":"234","author":"Smith","year":"2017","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib68","doi-asserted-by":"crossref","DOI":"10.2174\/1874473710666170321122226","article-title":"The behavioral profile of methylenedioxypyrovalerone (MDPV) and alpha-pyrrolidinopentiophenone (PVP) - a systematic review","author":"Stanciu","year":"2017","journal-title":"Curr. Drug Abuse Rev."},{"issue":"4","key":"10.1016\/j.neuropharm.2017.10.007_bib69","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/jat\/bkv011","article-title":"A\u00a0fatal case of pentedrone and alpha-pyrrolidinovalerophenone poisoning","volume":"39","author":"Sykutera","year":"2015","journal-title":"J.\u00a0Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib70","series-title":"\u03b1-pyrrolidinoketones","author":"Thomae","year":"1963"},{"key":"10.1016\/j.neuropharm.2017.10.007_bib71","series-title":"Decision 58\/12-Inclusion of 3,4-methylenedioxypyrovalerone (MDPV) in Schedule II of the Convention on Psychotropic Substances of 1971.74","author":"UNODC","year":"2015"},{"key":"10.1016\/j.neuropharm.2017.10.007_bib72","series-title":"World Drug Report 2016","author":"UNODC, United Nations Office on Drugs and Crime","year":"2016"},{"issue":"8","key":"10.1016\/j.neuropharm.2017.10.007_bib73","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s00204-015-1653-z","article-title":"3,4-Methylenedioxypyrovalerone (MDPV): in\u00a0vitro mechanisms of hepatotoxicity under normothermic and hyperthermic conditions","volume":"90","author":"Valente","year":"2016","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib74","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12888-016-1002-7","article-title":"Psychosis associated with acute recreational drug toxicity: a European case series","volume":"16","author":"Vallersnes","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.neuropharm.2017.10.007_bib75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/imj.13307","article-title":"Multi-organ dysfunction due to bath salts: are we aware of this entity?","volume":"47","author":"Valsalan","year":"2017","journal-title":"Intern Med. J."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib76","series-title":"\u03b1-Pyrrolidinovalerophenones","author":"Wander","year":"1963"},{"key":"10.1016\/j.neuropharm.2017.10.007_bib77","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13722-015-0024-7","article-title":"Designer drugs 2015: assessment and management","volume":"10","author":"Weaver","year":"2015","journal-title":"Addict. Sci. Clin. Pract."},{"issue":"11","key":"10.1016\/j.neuropharm.2017.10.007_bib78","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/jcph.742","article-title":"Mephedrone and 3,4-methylenedioxypyrovalerone (MDPV): synthetic cathinones with serious health implications","volume":"56","author":"White","year":"2016","journal-title":"J.\u00a0Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2017.10.007_bib79","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/jat\/bkw029","article-title":"Twenty-one cases involving alpha-pyrrolidinovalerophenone (alpha-PVP)","volume":"40","author":"Wright","year":"2016","journal-title":"J.\u00a0Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.10.007_bib80","doi-asserted-by":"crossref","first-page":"445e3","DOI":"10.1016\/j.ajem.2012.05.032","article-title":"Two cases of disseminated intravascular coagulation due to \u2018\u2018bath salts\u2019\u2019 resulting in fatalities, with laboratory confirmation","volume":"31","author":"Young","year":"2013","journal-title":"Am. J. Emerg. Med."},{"issue":"4","key":"10.1016\/j.neuropharm.2017.10.007_bib81","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/YCO.0000000000000066","article-title":"Mephedrone and other cathinones","volume":"27","author":"Zawilska","year":"2014","journal-title":"Curr. Opin. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2017.10.007_bib82","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.forsciint.2013.04.015","article-title":"Designer cathinones\u2013an emerging class of novel recreational drugs","volume":"231","author":"Zawilska","year":"2013","journal-title":"Forensic Sci. Int."},{"issue":"2","key":"10.1016\/j.neuropharm.2017.10.007_bib83","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11419-016-0353-6","article-title":"\u03b1-Pyrrolidinophenones: a new wave of designer cathinones","volume":"35","author":"Zawilska","year":"2017","journal-title":"Forensic Toxicol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817304744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817304744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T16:11:57Z","timestamp":1570205517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817304744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":83,"alternative-id":["S0028390817304744"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.10.007","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MDPV and \u03b1-PVP use in humans: The twisted sisters","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}